HR 913 - CLINICAL TREATMENT Act
Implementation of the Medicare Access and CHIP Re authorization Act
HR 3107 Improving Seniors' Timely Access to Care Act of 2019
Funding for the National Institute of Health including the National Cancer Institute, and the Food, and Drug Administration including the Oncology Centers of Excellence and funds authorized by the Tobacco Control Act.
Cancer Drug Parity Act (H.R. 1730/S. 741)
Safe Step Act (H.R. 2279/S. 2546)
Palliative Care Hospice Education and Training Act (H.R. 647/S. 2080)
Access to Infertility Treatment and Care Act (H.R. 2803/ S. 1461)
The Prescription Drug Pricing Reduction Act (S. 2543)
Mitigating Emergency Drug Shortages Act (S. 2723)
HR 2111/S 1048 Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act
S. 1541 Tobacco Free Youth Act
HR 2411/S 1258 Tobacco to 21 Act
Duration: January 1, 2008
to
January 1, 2020
General Issues: Medicare/Medicaid , Budget/Appropriations , Health Issues , Tobacco , Media (Information/Publishing) , Government Issues
Spending: about $3,487,835 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), U.S. Senate,, Centers For Medicare and Medicaid Services (CMS),, Office of Management & Budget (OMB), Office of Personnel Management (OPM)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2020
American Society of Clinical Oncology in-house lobbying effort was terminated on Feb. 24, 2020
Original Filing: 301142415.xml
4th Quarter, 2019
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 15, 2020.
Original Filing: 301106501.xml
Lobbying Issues
HR 913 - CLINICAL TREATMENT Act
Implementation of the Medicare Access and CHIP Re authorization Act
HR 3107 Improving Seniors' Timely Access to Care Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for the National Institute of Health including the National Cancer Institute, and the Food, and Drug Administration including the Oncology Centers of Excellence and funds authorized by the Tobacco Control Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Cancer Drug Parity Act (H.R. 1730/S. 741)
Safe Step Act (H.R. 2279/S. 2546)
Palliative Care Hospice Education and Training Act (H.R. 647/S. 2080)
Access to Infertility Treatment and Care Act (H.R. 2803/ S. 1461)
The Prescription Drug Pricing Reduction Act (S. 2543)
Mitigating Emergency Drug Shortages Act (S. 2723)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 2111/S 1048 Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act
S. 1541 Tobacco Free Youth Act
HR 2411/S 1258 Tobacco to 21 Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2019
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301079146.xml
Lobbying Issues
HR 913 - CLINICAL TREATMENT Act
Implementation of the Medicare Access and CHIP Re authorization Act
HR 3107 Improving Seniors' Timely Access to Care Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for the National Institute of Health including the National Cancer Institute, and the Food, and Drug Administration including the Oncology Centers of Excellence and funds authorized by the Tobacco Control Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Cancer Drug Parity Act (H.R. 1730/S. 741)
Safe Step Act (H.R. 2279/S. 2546)
Palliative Care Hospice Education and Training Act (H.R. 647/S. 2080)
Access to Infertility Treatment and Care Act (H.R. 2803/ S. 1461)
The Prescription Drug Pricing Reduction Act (S. 2543)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 2111/S 1048 Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2019
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301057291.xml
Lobbying Issues
HR 913 - CLINICAL TREATMENT Act
Implementation of the Medicare Access and CHIP Re authorization Act
HR 3107 Improving Seniors' Timely Access to Care Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for the National Institute of Health including the National Cancer Institute, and the Food, and Drug Administration including the Oncology Centers of Excellence and funds authorized by the Tobacco Control Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Cancer Drug Parity Act (H.R. 1730/S. 741)
Safe Step Act (H.R. 2279)
Palliative Care Hospice Education and Training Act (H.R. 647/S. 2080)
Access to Infertility Treatment and Care Act (H.R. 2803/ S. 1461)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 2111/S 1048 Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act
S. 1541 Tobacco-Free Youth Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2019
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 22, 2019.
Original Filing: 301038606.xml
Lobbying Issues
HR 913 - CLINICAL TREATMENT Act
Implementation of the Medicare Access and CHIP Re authorization Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Funding for the National Institute of Health including the National Cancer Institute, and the Food, and Drug Administration including the Oncology Centers of Excellence and funds authorized by the Tobacco Control Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Cancer Drug Parity Act (H.R. 1730/S. 741)
Safe Step Act (H.R. 2279)
Palliative Care Hospice Education and Training Act (H.R. 647)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 2111/S 1048 Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2018
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 23, 2019.
Original Filing: 301018262.xml
Lobbying Issues
H.R. 6836, the CLINICAL TREATMENT Act
H.R. 4841, the Standardizing Electronic Prior Authorization for Safe Prescribing Act
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017
Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2018 and FY 2019 appropriations related to the National Institutes of Health (NIH), National Cancer Institute (NCI),Food and Drug Administration (FDA), and the Cancer Moonshot Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1409 - Cancer Drug Parity Act of 2017
H.R.820/ S. 292 - Childhood Cancer STAR Act
H.R.1231/S. 456 - RACE for Children Act
H.R.1676/S. 693 - Palliative Care and Hospice Education and Training Act
H.R.878 - Right to Try Act of 2017
S.204 - Trickett Wendler Right to Try Act of 2017
H.R.1854/ S. 778 - Prescription Drug Monitoring Act of 2017
Diagnostic Accuracy and Innovation Act (DAIA)(Draft legislation)
H.R. 2430 FDA Reauthorization Act
S. 934 FDA Reauthorization Act
H.R. 2797/ S.1334Patient Choice and Quality Care Act (PCQCA)
H.R. 2999Patient's Access to Treatment Act (PATA)
H.R. 1628Better Care Reconciliation Act (BCRA)
H.R. 1316Prescription Drug Pricing Transparency Act
H.R. 2077 Restoring Patients Voices Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1136 FDA Deeming Authority Clarification Act of 2017
S.294/H.R.564 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2017
H.R. 4273/S.2100 Tobacco to 21 Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FASTR Act (Free Access to Science and Technology Research Act)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
3rd Quarter, 2018
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 23, 2018.
Original Filing: 300998950.xml
Lobbying Issues
H.R. 6836, the CLINICAL TREATMENT Act
H.R. 4841, the Standardizing Electronic Prior Authorization for Safe Prescribing Act
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017
Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2018 and FY 2019 appropriations related to the National Institutes of Health (NIH), National Cancer Institute (NCI),Food and Drug Administration (FDA), and the Cancer Moonshot Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1409 - Cancer Drug Parity Act of 2017
H.R.820/ S. 292 - Childhood Cancer STAR Act
H.R.1231/S. 456 - RACE for Children Act
H.R.1676/S. 693 - Palliative Care and Hospice Education and Training Act
H.R.878 - Right to Try Act of 2017
S.204 - Trickett Wendler Right to Try Act of 2017
H.R.1854/ S. 778 - Prescription Drug Monitoring Act of 2017
Diagnostic Accuracy and Innovation Act (DAIA)(Draft legislation)
H.R. 2430 FDA Reauthorization Act
S. 934 FDA Reauthorization Act
H.R. 2797/ S.1334Patient Choice and Quality Care Act (PCQCA)
H.R. 2999Patient's Access to Treatment Act (PATA)
H.R. 1628Better Care Reconciliation Act (BCRA)
H.R. 1316Prescription Drug Pricing Transparency Act
H.R. 2077 Restoring Patients Voices Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1136 FDA Deeming Authority Clarification Act of 2017
S.294/H.R.564 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2017
H.R. 4273/S.2100 Tobacco to 21 Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FASTR Act (Free Access to Science and Technology Research Act)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
2nd Quarter, 2018
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 20, 2018.
Original Filing: 300977362.xml
Lobbying Issues
H.R. 4841, the Standardizing Electronic Prior Authorization for Safe Prescribing Act
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017
Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2018 and FY 2019 appropriations related to the National Institutes of Health (NIH), National Cancer Institute (NCI),Food and Drug Administration (FDA), and the Cancer Moonshot Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1409 - Cancer Drug Parity Act of 2017
H.R.820/ S. 292 - Childhood Cancer STAR Act
H.R.1231/S. 456 - RACE for Children Act
H.R.1676/S. 693 - Palliative Care and Hospice Education and Training Act
H.R.878 - Right to Try Act of 2017
S.204 - Trickett Wendler Right to Try Act of 2017
H.R.1854/ S. 778 - Prescription Drug Monitoring Act of 2017
Diagnostic Accuracy and Innovation Act (DAIA)(Draft legislation)
H.R. 2430 FDA Reauthorization Act
S. 934 FDA Reauthorization Act
H.R. 2797/ S.1334Patient Choice and Quality Care Act (PCQCA)
H.R. 2999Patient's Access to Treatment Act (PATA)
H.R. 1628Better Care Reconciliation Act (BCRA)
H.R. 1316Prescription Drug Pricing Transparency Act
H.R. 2077 Restoring Patients Voices Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1136 FDA Deeming Authority Clarification Act of 2017
S.294/H.R.564 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2017
H.R. 4273/S.2100 Tobacco to 21 Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FASTR Act (Free Access to Science and Technology Research Act)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
1st Quarter, 2018
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 19, 2018.
Original Filing: 300951229.xml
Lobbying Issues
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017
Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2017 and FY 2018 appropriations related to the National Institutes of Health (NIH), National Cancer Institute (NCI),Food and Drug Administration (FDA), and the Cancer Moonshot Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1409 - Cancer Drug Parity Act of 2017
H.R.820/ S. 292 - Childhood Cancer STAR Act
H.R.1231/S. 456 - RACE for Children Act
H.R.1676/S. 693 - Palliative Care and Hospice Education and Training Act
H.R.878 - Right to Try Act of 2017
S.204 - Trickett Wendler Right to Try Act of 2017
H.R.1854/ S. 778 - Prescription Drug Monitoring Act of 2017
Diagnostic Accuracy and Innovation Act (DAIA)(Draft legislation)
H.R. 2430 FDA Reauthorization Act
S. 934 FDA Reauthorization Act
H.R. 2797/ S.1334Patient Choice and Quality Care Act (PCQCA)
H.R. 2999Patient's Access to Treatment Act (PATA)
H.R. 1628Better Care Reconciliation Act (BCRA)
H.R. 1316Prescription Drug Pricing Transparency Act
H.R. 2077 Restoring Patients Voices Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1136 FDA Deeming Authority Clarification Act of 2017
S.294/H.R.564 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2017
H.R. 4273/S.2100 Tobacco to 21 Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FASTR Act (Free Access to Science and Technology Research Act)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
4th Quarter, 2017
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 22, 2018.
Original Filing: 300936072.xml
Lobbying Issues
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017
Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2017 and FY 2018 appropriations related to the National Institutes of Health (NIH), National Cancer Institute (NCI),Food and Drug Administration (FDA), and the Cancer Moonshot Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1409 - Cancer Drug Parity Act of 2017
H.R.820/ S. 292 - Childhood Cancer STAR Act
H.R.1231/S. 456 - RACE for Children Act
H.R.1676/S. 693 - Palliative Care and Hospice Education and Training Act
H.R.878 - Right to Try Act of 2017
S.204 - Trickett Wendler Right to Try Act of 2017
H.R.1854/ S. 778 - Prescription Drug Monitoring Act of 2017
Diagnostic Accuracy and Innovation Act (DAIA)(Draft legislation)
H.R. 2430 FDA Reauthorization Act
S. 934 FDA Reauthorization Act
H.R. 2797/ S.1334Patient Choice and Quality Care Act (PCQCA)
H.R. 2999Patient's Access to Treatment Act (PATA)
H.R. 1628Better Care Reconciliation Act (BCRA)
H.R. 1316Prescription Drug Pricing Transparency Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1136 FDA Deeming Authority Clarification Act of 2017
S.294/H.R.564 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2017
H.R. 4273/S.2100 Tobacco to 21 Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FASTR Act (Free Access to Science and Technology Research Act)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
3rd Quarter, 2017
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 20, 2017.
Original Filing: 300912111.xml
Lobbying Issues
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017
Implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
Implementation of Protecting Access to Medicare Act of 2014 (PAMA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2017 and FY 2018 appropriations related to the National Institutes of Health (NIH), National Cancer Institute (NCI),Food and Drug Administration (FDA), and the Cancer Moonshot Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1409 - Cancer Drug Parity Act of 2017
H.R.820/ S. 292 - Childhood Cancer STAR Act
H.R.1231/S. 456 - RACE for Children Act
H.R.1676/S. 693 - Palliative Care and Hospice Education and Training Act
H.R.878 - Right to Try Act of 2017
S.204 - Trickett Wendler Right to Try Act of 2017
H.R.1854/ S. 778 - Prescription Drug Monitoring Act of 2017
Diagnostic Accuracy and Innovation Act (DAIA)(Draft legislation)
H.R. 2430 FDA Reauthorization Act
S. 934 FDA Reauthorization Act
H.R. 2797/ S.1334Patient Choice and Quality Care Act (PCQCA)
H.R. 2999Patient's Access to Treatment Act (PATA)
H.R. 1628Better Care Reconciliation Act (BCRA)
H.R. 1316Prescription Drug Pricing Transparency Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1136 FDA Deeming Authority Clarification Act of 2017
S.294/H.R.564 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2017
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FASTR Act (Free Access to Science and Technology Research Act)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
2nd Quarter, 2017
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300895950.xml
Lobbying Issues
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2017 and FY 2018 appropriations related to the National Institutes of Health (NIH), National Cancer Institute (NCI),Food and Drug Administration (FDA), and the Cancer Moonshot Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1409 - Cancer Drug Parity Act of 2017
H.R.820/ S. 292 - Childhood Cancer STAR Act
H.R.1231/S. 456 - RACE for Children Act
H.R.1676/S. 693 - Palliative Care and Hospice Education and Training Act
H.R.878 - Right to Try Act of 2017
S.204 - Trickett Wendler Right to Try Act of 2017
H.R.1854/ S. 778 - Prescription Drug Monitoring Act of 2017
Diagnostic Accuracy and Innovation Act (DAIA)(Draft legislation)
H.R. 2430 FDA Reauthorization Act
S. 934 FDA Reauthorization Act
H.R. 1628American Health Care Act (AHCA)
H.R. 2797/ S.1334Patient Choice and Quality Care Act (PCQCA)
H.R. 2999Patient's Access to Treatment Act (PATA)
H.R. 1628Better Care Reconciliation Act (BCRA)
HR 1703Medical ProductCommunicationsAct of 2017
H.R. 1316Prescription Drug Pricing Transparency Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1136 FDA Deeming Authority Clarification Act of 2017
S.294/H.R.564 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2017
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FASTR Act (Free Access to Science and Technology Research Act)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
1st Quarter, 2017
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 24, 2017.
Original Filing: 300879021.xml
Lobbying Issues
H.R.1834/S. 463 - Cancer Care Payment Reform Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2017 and FY 2018 appropriations related to the National Institutes of Health (NIH), National Cancer Institute (NCI),Food and Drug Administration (FDA, and the Cancer Moonshot Initiative
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.1409 - Cancer Drug Parity Act of 2017
H.R.820/ S. 292 - Childhood Cancer STAR Act
H.R.1231/S. 456 - RACE for Children Act
H.R.1676/S. 693 - Palliative Care and Hospice Education and Training Act
H.R.878 - Right to Try Act of 2017
S.204 - Trickett Wendler Right to Try Act of 2017
H.R.1854/ S. 778 - Prescription Drug Monitoring Act of 2017
Diagnostic Accuracy and Innovation Act (DAIA)(Draft legislation)
FDA User Fee Reauthorization
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1136 FDA Deeming Authority Clarification Act of 2017
S.294/H.R.564 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2017
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FASTR Act (Free Access to Science and Technology Research Act)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
4th Quarter, 2016
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 23, 2017.
Original Filing: 300857900.xml
Lobbying Issues
HR 5122, legislation to prohibit further action on the Centers for Medicare & Medicaid Services (CMS) proposed rule for the Medicare Part B Drug Demo
H.R. 5001/S.2822, the Flexibility in Electronic Health Record (EHR) Reporting Act
HR 1416 The Cancer Patient Protection Act of 2015
Implementation of the Medicare Access and CHIP Reauthorization Act of 2015
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2017 Appropriations related to the National Institutes of Health, National Cancer Institute, and Food & Drug Administration, including Continuing Resolution
S 318/HR 531 Accelerating Biomedical Research Act
S 289/HR 2104 American Cures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 524 Comprehensive Addiction and Recovery Act of 2016
Senate HELP Committee Innovations Package
HR 6 21st Century Cures Act
HR 1600 Patients Access to Treatment Act of 2015
HR 2739/S 1566 Cancer Drug Coverage Parity Act
HR 3381/S 1883 Childhood Cancer STAR Act
HR 3119 Palliative Care Hospice Education and Training Act
S 2141 Transparent Ratings on Usability and Security to Transform Information Technology (TRUST IT) Act of 2015
H.R. 2846 Planning Actively for Cancer Treatment (PACT) Act of 2015
S. 2511 Improving Health Information Technology Act
Reforms to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 662 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2015
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 779/HR 1477 FASTR Act (Free Access to Science and Technology Research Act)
HR 293 To amend title XI of the Social Security Act to exempt from manufacturer transparency reporting certain transfers used for educational purposes, and for other purposes
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
3rd Quarter, 2016
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 21, 2016.
Original Filing: 300840398.xml
Lobbying Issues
HR 5122, legislation to prohibit further action on the Centers for Medicare & Medicaid Services (CMS) proposed rule for the Medicare Part B Drug Demo
H.R. 5001/S.2822, the Flexibility in Electronic Health Record (EHR) Reporting Act
HR 1416 The Cancer Patient Protection Act of 2015
Implementation of the Medicare Access and CHIP Reauthorization Act of 2015
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2017 Appropriations related to the National Institutes of Health, National Cancer Institute, and Food & Drug Administration, including Continuing Resolution
S 318/HR 531 Accelerating Biomedical Research Act
S 289/HR 2104 American Cures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 524 Comprehensive Addiction and Recovery Act of 2016
Senate HELP Committee Innovations Package
HR 6 21st Century Cures Act
HR 1600 Patients Access to Treatment Act of 2015
HR 2739/S 1566 Cancer Drug Coverage Parity Act
HR 3381/S 1883 Childhood Cancer STAR Act
HR 3119 Palliative Care Hospice Education and Training Act
S 2141 Transparent Ratings on Usability and Security to Transform Information Technology (TRUST IT) Act of 2015
H.R. 2846 Planning Actively for Cancer Treatment (PACT) Act of 2015
S. 2511 Improving Health Information Technology Act
Reforms to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 662 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2015
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 779/HR 1477 FASTR Act (Free Access to Science and Technology Research Act)
HR 293 To amend title XI of the Social Security Act to exempt from manufacturer transparency reporting certain transfers used for educational purposes, and for other purposes
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
2nd Quarter, 2016
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 20, 2016.
Original Filing: 300818187.xml
Lobbying Issues
HR 5122, legislation to prohibit further action on the Centers for Medicare & Medicaid Services (CMS) proposed rule for the Medicare Part B Drug Demo
H.R. 5001/S.2822, the Flexibility in Electronic Health Record (EHR) Reporting Act
HR 1416 The Cancer Patient Protection Act of 2015
Implementation of the Medicare Access and CHIP Reauthorization Act of 2015
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2017 Appropriations related to the National Institutes of Health, National Cancer Institute, and Food & Drug Administration
S 318/HR 531 Accelerating Biomedical Research Act
S 289/HR 2104 American Cures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 524 Comprehensive Addiction and Recovery Act of 2016
Senate HELP Committee Innovations Package
HR 6 21st Century Cures Act
HR 1600 Patients Access to Treatment Act of 2015
HR 2739/S 1566 Cancer Drug Coverage Parity Act
HR 3381/S 1883 Childhood Cancer STAR Act
HR 3119 Palliative Care Hospice Education and Training Act
S 2141 Transparent Ratings on Usability and Security to Transform Information Technology (TRUST IT) Act of 2015
H.R. 2846 Planning Actively for Cancer Treatment (PACT) Act of 2015
S. 2511 Improving Health Information Technology Act
Reforms to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 662 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2015
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 779/HR 1477 FASTR Act (Free Access to Science and Technology Research Act)
HR 293 To amend title XI of the Social Security Act to exempt from manufacturer transparency reporting certain transfers used for educational purposes, and for other purposes
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
1st Quarter, 2016
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 20, 2016.
Original Filing: 300797786.xml
Lobbying Issues
HR 1416 The Cancer Patient Protection Act of 2015
Implementation of the Medicare Access and CHIP Reauthorization Act of 2015
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FY 2017 Appropriations related to the National Institutes of Health, National Cancer Institute, and Food & Drug Administration
S 318/HR 531 Accelerating Biomedical Research Act
S 289/HR 2104 American Cures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Senate HELP Committee Innovations Package
HR 6 21st Century Cures Act
HR 1600 Patients Access to Treatment Act of 2015
HR 2739/S 1566 Cancer Drug Coverage Parity Act
HR 3381/S 1883 Childhood Cancer STAR Act
HR 3119 Palliative Care Hospice Education and Training Act
S 2141 Transparent Ratings on Usability and Security to Transform Information Technology (TRUST IT) Act of 2015
H.R. 2846 Planning Actively for Cancer Treatment (PACT) Act of 2015
S. 2511 Improving Health Information Technology Act
S.524 Comprehensive Addiction and Recovery Act of 2016
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 662 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2015
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 779/HR 1477 FASTR Act (Free Access to Science and Technology Research Act)
HR 293 To amend title XI of the Social Security Act to exempt from manufacturer transparency reporting certain transfers used for educational purposes, and for other purposes
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
4th Quarter, 2015
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300784401.xml
Lobbying Issues
HR 1416 The Cancer Patient Protection Act of 2015
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 2029- The Consolidated Appropriations Act of 2016
H.R.1314 - Bipartisan Budget Act of 2015
S 1695/HR 3020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
S 1800/HR 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016
S 318/HR 531 Accelerating Biomedical Research Act
S 289/HR 2104 American Cures Act
HR 719 Continuing Appropriations Act, 2016
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Senate HELP Committee Innovations Package
HR 6 21st Century Cures Act
HR 1600 Patients Access to Treatment Act of 2015
HR 2739/S 1566 Cancer Drug Coverage Parity Act
HR 3381/S 1883 Childhood Cancer STAR Act
HR 3119 Palliative Care Hospice Education and Training Act
S 2141 Transparent Ratings on Usability and Security to Transform Information Technology (TRUST IT) Act of 2015
H.R. 2846 Planning Actively for Cancer Treatment (PACT) Act of 2015
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 662 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2015
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 779/HR 1477 FASTR Act (Free Access to Science and Technology Research Act)
HR 293 To amend title XI of the Social Security Act to exempt from manufacturer transparency reporting certain transfers used for educational purposes, and for other purposes
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
3rd Quarter, 2015
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 20, 2015.
Original Filing: 300762508.xml
Lobbying Issues
HR 1416 The Cancer Patient Protection Act of 2015
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 1695/HR 3020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
S 1800/HR 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016
S 318/HR 531 Accelerating Biomedical Research Act
S 289/HR 2104 American Cures Act
HR 719 Continuing Appropriations Act, 2016
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 6 21st Century Cures Act
HR 1600 Patients Access to Treatment Act of 2015
HR 2739/S 1566 Cancer Drug Coverage Parity Act
HR 3381/S 1883 Childhood Cancer STAR Act
HR 3119 Palliative Care Hospice Education and Training Act
S 2141 Transparent Ratings on Usability and Security to Transform Information Technology (TRUST IT) Act of 2015
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 662 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2015
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 779/HR 1477 FASTR Act (Free Access to Science and Technology Research Act)
HR 293 To amend title XI of the Social Security Act to exempt from manufacturer transparency reporting certain transfers used for educational purposes, and for other purposes
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Media (Information/Publishing)
2nd Quarter, 2015
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 20, 2015.
Original Filing: 300746930.xml
Lobbying Issues
HR 2 The Medicare Access and CHIP Reauthorization Act
HR 1416 The Cancer Patient Protection Act of 2015
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 1695/HR 3020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
S 1800/HR 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016
S 318/HR 531 Accelerating Biomedical Research Act
S 289/HR 2104 American Cures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 6 21st Century Cures Act
HR 1600 Patients Access to Treatment Act of 2015
HR 2739/S 1566 Cancer Drug Coverage Parity Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 662 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2015
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2015
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 22, 2015.
Original Filing: 300728527.xml
Lobbying Issues
HR 2 The Medicare Access and CHIP Reauthorization Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), and Food & Drug Administration (FDA)
S 318/HR 531, Accelerating Biomedical Research Act
S 289, American Cures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Draft legislation related to the House Energy & Commerce Committee's 21st Century Cures Initiative
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2014
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 30, 2015.
Original Filing: 300710029.xml
Lobbying Issues
HR 4015/S 2000 SGR Repeal and Medicare Provider Payment Modernization Act of 2014
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General appropriations related to the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration. S 2115 the America Cures Act. HR4384 the America Heals Act. S 2658/HR 5580 the Accelerating Biomedical Research Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 5214 Requires the Secretary of Health and Human Services (HHS) to consult with clinical experts and make recommendations for the use of clinical data registries to improve patient care. S 1879/HR 1801 Cancer Treatment Parity Act of 2013. HR 3033 The SOFTWARE Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 313/S 1347 A bill to provide transparency, accountability, and limitation of government sponsored conferences.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2014
American Society of Clinical Oncology amended a lobbying report for in-house lobbying in Q32014 on July 11, 2016
Original Filing: 300807952.xml
Lobbying Issues
HR 4015/S 2000 SGR Repeal and Medicare Provider Payment Modernization Act of 2014.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General appropriations related to the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration. S 2115 The America Cures Act. HR 4384 the America Heals Act. S 2658/HR 5580 The Accelerating Biomedical Research Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Natl Institutes of Health (NIH)
Lobbying Issues
HR 5214 Requires the Secretary of Health and Human Services (HHS) to consult with clinical experts and make recommendations for the use of clinical data registries to improve patient care. S 1879/HR 1801 Cancer Treatment Parity Act of 2013. HR 3033 The SOFTWARE Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 313/S 1347 A bill to provide transparency, accountability and limitations of government sponsored conferences.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 20, 2014.
Original Filing: 300686910.xml
Lobbying Issues
HR 4015/S 2000 SGR Repeal and Medicare Provider Payment Modernization Act of 2014.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General appropriations related to the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration. S 2115 The America Cures Act. HR 4384 the America Heals Act. S 2658/HR 5580 The Accelerating Biomedical Research Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Natl Institutes of Health (NIH)
Lobbying Issues
HR 5214 Requires the Secretary of Health and Human Services (HHS) to consult with clinical experts and make recommendations for the use of clinical data registries to improve patient care. S 1879/HR 1801 Cancer Treatment Parity Act of 2013. HR 3033 The SOFTWARE Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 313/S 1347 A bill to provide transparency, accountability and limitations of government sponsored conferences.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 5, 2015.
Original Filing: 300692742.xml
Lobbying Issues
The Sustainable Growth Rate, HR 4015/S 2000 SGR Repeal and Medicare Provider Payment Modernization Act; HR 1416, Cancer Patient and Protection Act of 2013
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General appropriations related to the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2014
American Society of Clinical Oncology amended a lobbying report for in-house lobbying in Q12014 on Jan. 5, 2015
Original Filing: 300692754.xml
Lobbying Issues
HR 4015/S 2000 SGR Repeal and Medicare Provider Payment Modernization Act of 2014
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General appropriations related to the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration. HR 2019, the Gabriella Miller Kids First Research Act of 2013. S 2115 the America Cures Act. HR 4384 the America Heals Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 21, 2014.
Original Filing: 300647604.xml
Lobbying Issues
HR 4015/S 2000 SGR Repeal and Medicare Provider Payment Modernization Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General appropriations related to the National Institutes of Health, the National Cancer Insitute and the Food and Drug Administration. HR 2019 the Gabriella Miller Kids First Research Act of 2013. S 2115 the America Cures Act. HR 4384 the America Heals Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH)
Lobbying Issues
HR 3033 The SOFTWARE Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 30, 2014.
Original Filing: 300629611.xml
Lobbying Issues
HR 800/S 806 To amend Part B of Title XVIII of the Social Security Act to exlude customary prompt pay discounts from manufacturers to wholesalers for the average sales price for drugs and biologicals under Medicare
HR 1416 Cancer Patient Protection Act of 2013; HR 2477 The Planning Actively for Cancer Treatment (PACT) Act; HR 2810 Medicare Pateint Access and Quality Improvement Act of 2013; The SGR Repeal and Medicare Beneficiary Improvement Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Appropriations related to the National Institutes of Health, The National Cancer Institute, and the Food and Drug Administration. HR 2019 The Kids First Research Act of 2013. Bipartisan Budget Act of 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 1801/S 1879 Cancer Drug Coverage Parity Act of 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 21, 2013.
Original Filing: 300605246.xml
Lobbying Issues
HR 800/S 806 To amend Part B of Title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare
HR 1416 Cancer Patient Protection Act of 2013; HR 2477, The Planning Actively for Cancer Treatment (PACT) Act
Issues related to the Sustainable Growth Rate. HR 2810 Medicare Patient Access and Quality Improvement Act of 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
General appropriations related to the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration. HR 2019 The Kids First Research Act of 2013; Issues related to sequestration and the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration; S 1413 FDA User Fee Protection Act; HR 2725 FDA Safety Over Sequestration Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 1801 Cancer Drug Coverage Parity Act of 2013
S 641 Palliative Care and Hospice Education Training Act
S 351 Independent Payment Advisory Board (IPAB), the Protecting Seniors' Access to Medicare Act of 2013
HR 1666 Patient Centered Quality Care for Life Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2013
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 19, 2013.
Original Filing: 300577576.xml
Lobbying Issues
HR 800/S 806 To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
HR 1416 Cancer Patient Protection Act of 2013
Medicare Physician Payment Innovation Act of 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
General appropriations related to the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration. Issues related to sequestration and the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration.
HR 2019 The Kids First Research Act of 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 1801 Cancer Drug Coverage Parity Act of 2013
S 641 Palliative Care and Hospice Education and Training Act
S 351 Independent Payment Advisory Board (IPAB), the Protecting Seniors' Access to Medicare Act of 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 194 Tobacco Tax Equity Act
1st Quarter, 2013
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 19, 2013.
Original Filing: 300557310.xml
Lobbying Issues
HR 800 - To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicas under Medicare. General issues related to the sustainable growth rate. Issues related to the application of sequestration to Part B drugs. Issues related to clinical data registries.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
General appropriations related to the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration. Issues related to sequestration and the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to cancer drug coverage parity.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2012
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 15, 2013.
Original Filing: 300529077.xml
Lobbying Issues
General appropriations related to the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration. Issues related to sequestration and the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 905 / S 733 - To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicasl under Medicare. General issues related to the sustainable growth rate. General issues related to clinical data registries participation in quality reporting for Medicare.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 2746, the Cancer Drug Coverage Parity Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 22, 2012.
Original Filing: 300517559.xml
Lobbying Issues
General Appropriations related to cancer research, the National Institutes of Health, The National Cancer Institute and the Food and Drug Administration. Impact of sequestration on cancer research and oncology services under Medicare.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 905/733: A bill to amend Part B of Title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologics under Medicare. General issues related to the sustainable growth rate, physician payment reform and quality reporting.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2012
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 20, 2012.
Original Filing: 300494388.xml
Lobbying Issues
General Appropriations related to cancer research, the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 296/H.R. 2245 Preserving Access to Life-Saving Medications Act
Drug shortages provisions of PDUFA
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA)
Lobbying Issues
H.R. 905/S 733. Al bill to amend Part B of Title XVIII of the SOcial Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from teh aaverage sales price for durgs and biologics under Medicare. General issues related to the sustainable growth rate, physician payment reform and ASP.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 19, 2012.
Original Filing: 300466952.xml
Lobbying Issues
General appropriations related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 296 / HR 2245, Preserving Access to Life-Saving Medications Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
HR 905 / S 733 - To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicasl under Medicare. General issues related to the sustainable growth rate.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 27, 2012.
Original Filing: 300454433.xml
Lobbying Issues
General appropriations related to cancer research, the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 296/HR 2245, Preserving Access to Life-Saving Medications Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
H.R. 905/S 733 - To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare. Proposed cuts to Part B drugs in debt ceiling negotiations and by the Joint Select Committee on Deficit Reduction. General issues related to the sustainable growth rate (SGR).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 19, 2011.
Original Filing: 300422225.xml
Lobbying Issues
General appropriations related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 296 Preserving Access to Life-Saving Medications Act of 2011; HR 2245 Preserving Access to Life-Saving Medications Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
HR 905 To amend Part B of Title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales proce for drugs and biologicals under Medicare; S 733 A bill to amend Part B of Title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; General issues related to the sustainable growth rate (SGR), average sales price (ASP);General cuts to the Average Sales Price (ASP) under consideration during the debt-ceiling debate, and by the Joint Select Committee on Deficit Reduction.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 20, 2011.
Original Filing: 300402190.xml
Lobbying Issues
General appropriations related to cancer research, the National Institutes of Health, the National Cancer Institute and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 296 Preserving Access to Life-Saving Medications Act of 2011
H.R. 2245 Preserving Access to Life-Saving Medications Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
Lobbying Issues
H.R. 905 To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.; S. 733 A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; General issues related to the sustainable growth rate and ASP.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 20, 2011.
Original Filing: 300374371.xml
Lobbying Issues
General appropriations related to cancer research, the National Institutes of Health, the National Cancer Institute and teh Food and Drug Administration
6th & 7th Continuing Resolution for FY 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 296, Preserving Access to Life-Saving Medications Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
Lobbying Issues
H.R. 905 - To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
S. 733 To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 18, 2011.
Original Filing: 300341681.xml
Lobbying Issues
General Appropriations issues related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
H J Res 101, 2nd Continuing Resolution; H J Res 105, 3rd Continuing Resolution; HR 3028 FY 2011 Continuing Resolution through March 4, 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1844, Comprehensive Cancer Care Improvement Act, seeking cosponsors
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1392 and S. 1221- an act to ensure more appropriate payment for drugs under Medicaer Part B; seeking cosponsors
Medicare Reimbursement for Chemotherapy Drugs
H.R. 3095, Medicare Cancer Patient Database and Coverage Act, seeking cosponsors
H.R. 4994, Medicare and Medicaid Extenders Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
3rd Quarter, 2010
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 6, 2010.
Original Filing: 300309035.xml
Lobbying Issues
General Appropriations issues related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
S. 3686 FY 2011 Labor, HHS, Education, and Related Agencies Appropriations Bill
H.R. 3081 FY 2011 Continuing Resolution October 1-December 3, 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1844, Comprehensive Cancer Care Improvement Act, seeking cosponsors
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1392 and S. 1221- an act to ensure more appropriate payment for drugs under Medicaer Part B; seeking cosponsors
Medicare Reimbursement for Chemotherapy Drugs
H.R. 3095, Medicare Cancer Patient Database and Coverage Act, seeking cosponsors
SGR Repeal, advocacy for the repeal and temporary SGR extension (H.R. 3962, Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
2nd Quarter, 2010
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 15, 2010.
Original Filing: 300307992.xml
Lobbying Issues
General Appropriations issues related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1844, Comprehensive Cancer Care Improvement Act, seeking cosponsors
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1392 and S. 1221- an act to ensure more appropriate payment for drugs under Medicaer Part B; seeking cosponsors
Medicare Reimbursement for Chemotherapy Drugs
H.R. 3095, Medicare Cancer Patient Database and Coverage Act, seeking cosponsors
SGR Repeal, advocacy for the repeal and temporary SGR extensions (H.R. 4213, a bill to extend certain tax policies and stimulate job growth; H.R. 4581, the Continuing Extensions Act of 2010; and H.R. 3962, Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010.)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB)
1st Quarter, 2010
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 15, 2010.
Original Filing: 300258443.xml
Lobbying Issues
General Appropriations issues related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 488/H.R. 716, Access to Cancer Clinical Trials Act, seeking cosponsors
H.R. 1844, Comprehensive Cancer Care Improvement Act, seeking cosponsors
H.R. 3590, The Patient Protection and Affordable Care Act, seeking support for the clinical trials amendment
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1392 and S. 1221- an act to ensure more appropriate payment for drugs under Medicaer Part B; seeking cosponsors
Medicare Reimbursement for Chemotherapy Drugs
H.R. 3095, Medicare Cancer Patient Database and Coverage Act, seeking cosponsors
H.R. 3961, Medicare Physician Payment Reform Act of 2009, SGR Repeal, advocacy for the repeal and temporary SGR extensions (H.R. 4213, a bill to extend certain tax policies and stimulate job growth; and H.R. 4581, the Continuing Extensions Act of 2010.)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2009
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 20, 2010.
Original Filing: 300240444.xml
Lobbying Issues
H.R. 3293, Labor-HHS-Education Appropriations for FY 2010
H.R. 3288, Consolidated Appropriations Act for Fy 2010
General Appropriations issues related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 488/H.R. 716, Access to Cancer Clinical Trials Act, seeking cosponsors
H.R. 1844, Comprehensive Cancer Care Improvement Act, seeking cosponsors
H.R. 3590, The Patient Protection and Affordable Care Act/H.R Affordable Health Care for America Act, seeking support for a clinical trials amendment
H.R. 3590, The Patient Protection and Affordable Care Act/H.R Affordable Health Care for America Act, seeking support for a prompt pay amendment.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1392 and S. 1221- To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program, seeking cosponsors
Medicare Reimbursement for Chemotherapy Drugs
H.R. 3095, Medicare Cancer Patient Database and Coverage Act, seeking cosponsorsS. 1776, Medicare Physician Fairness Act of 2009/H.R. 3961, Medicare Physician Payment Reform Act of 2009, (SGR repeal) advocated for both bills
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2009
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 16, 2009.
Original Filing: 300206867.xml
Lobbying Issues
H.R. 3293, Labor-HHS-Education Appropriations for FY 2010
H.R. 2997, Agriculture-FDA Appropriations for FY 2010
General Appropriations issues related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 488/H.R. 716, Access to Cancer Clinical Trials Act, seeking cosponsors
H.R. 1844, Comprehensive Cancer Care Improvement Act, seeking cosponsors
H.R.2109, Childhood Cancer Survivorship Research and Quality of Life Act, seeking cosponsors
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 1392 and S. 1221- To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program, seeking cosponsors
Medicare Reimbursement for Chemotherapy Drugs
H.R. 3095, Medicare Cancer Patient Database and Coverage Act, seeking cosponsors
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2009
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 17, 2009.
Original Filing: 300184156.xml
Lobbying Issues
General Appropriations issues related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 717, 21st Century Cancer ALERT Act - discussions of draft language
S. 488/H.R. 716, Access to Cancer Clinical Trials Act, seeking cosponsors, met with OPM for FEHBP coverage of clinical trials
H.R. 1844, Comprehensive Cancer Care Improvement Act, discussions of draft language; seeking cosponsors
H.R.2109, Childhood Cancer Survivorship Research and Quality of Life Act, discussions of draft language, seeking cosponsors
Agencies Lobbied
U.S. House of Representatives U.S. Senate Office of Personnel Management (OPM)
Lobbying Issues
H.R. 1392, To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program, seeking cosponsors
Medicare Reimbursement for Chemotherapy Drugs
H.R. 3095, Medicare Cancer Patient Database and Coverage Act, general discussions on drafting of the legislation
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2009
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 14, 2009.
Original Filing: 300148014.xml
Lobbying Issues
H.R. 1, The American Recovery and Reinvestment Act
H.R. 1105, FY 2009 Omnibus Appropriations Act
General Appropriations issues related to cancer research, the National Institutes of Health, the National Cancer Institute, and the Food and Drug Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 717, 21st Century Cancer ALERT Act
S. 488/H.R. 716, Access to Cancer Clinical Trials Act
H.R. 1548, the Pathway for Biosimilars Act
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine ActGeneral discussion on draft language for childhood cancer survivorship
General discussion on draft language for comprehensive care planning
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1392, To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program
Medicare Reimbursement for Chemotherapy Drugs
Medicare Coverage of Clinical Trials
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2008
American Society of Clinical Oncology amended a lobbying report for in-house lobbying in Q42008 on April 8, 2009
Original Filing: 300144799.xml
Lobbying Issues
Comprehensive Cancer Care Improvement Act
Medicare Reimbursement for Chemotherapy Drugs
Medicare Coverage of Clinical Trials
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
NIH/NCI Appropriations for FY 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Jan. 21, 2009.
Original Filing: 300129986.xml
Lobbying Issues
Medicare Reimbursement of Chemotherapy Drugs
Sustainable Growth Rate
Comprehensive Cancer Care Improvement Act
Medicare Coverage of Clinical Trials
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
American Society of Clinical Oncology amended a lobbying report for in-house lobbying in Q32008 on April 8, 2009
Original Filing: 300144770.xml
Lobbying Issues
Comprehensive Cancer Care Improviement Act - HR 1078
Medicare Reimbursement for Chemotherapy Drugs - HR 3011
Sustainable Growth Rate
Medicare Coverage of Clinical Trials
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
NIH/NCI Appropriations for FY2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, American Society of Clinical Oncology had in-house lobbyists. The report was filed on Oct. 20, 2008.
Original Filing: 300106200.xml
Lobbying Issues
Comprehensive Cancer Care Improviement Act - HR 1078
Medicare Reimbursement for Chemotherapy Drugs - HR 3011
Sustainable Growth Rate
Medicare Coverage of Clinical Trials
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
NIH/NCI Appropriations for FY2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2008
In Q2, American Society of Clinical Oncology had in-house lobbyists. The report was filed on July 21, 2008.
Original Filing: 300080141.xml
Lobbying Issues
Comprehensive Cancer Care Improvement Act - HR 1078
Medicare Reimbursement for Chemotherapy Drugs - HR 3011
Sustainable Growth Rate - HR 6331
Medicare Coverage of Clinical Trials
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
NIH/NCI Approprations for FY 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
In Q1, American Society of Clinical Oncology had in-house lobbyists. The report was filed on April 21, 2008.
Original Filing: 300051218.xml
Lobbying Issues
Comprehensive Cancer Care Improvement Act - HR1078
Medicare Reimbursement for Chemotherapy Drugs - HR3011
Sustainable Growth Rate
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
NIH/NCI Appropriations for FY 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Family Smoking Prevention and Tobacco Control Act
Genetic Information Nondiscrimination Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate